Not Yet RecruitingNCT07252752
Brain insulin and dopamine signaling in first-episode psychosis
About this title
Read the official source — NCT07252752Medication studyAges 18–40AustriaSchizophrenia
Understand this study
Who could participate?
Listed age limits: 18 years to 40 years.
- Listed locations
- ViennaSee all locations and recruitment
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateEstimated: January 1, 2026
- Recruitment status
- Not Yet Recruiting
- Enrollment listed in the registry
- 46
- Sponsor
- Medical University of Vienna
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Drug, Radiation
- Locations
- Austria
- Age range
- From 18 Years to 40 Years
- Official registry ID
- NCT07252752
- Official title
Show the full official title
Dopamine and Insulin in Psychosis: Imaging the Effects of Intranasal Insulin on Dopamine Transmission
Recruitment & locations
Not yet recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Vienna
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Medical University of Vienna, a university.
Does this study involve medication?
Yes. The study involves medication, including Intranasal Insulin, Placebo, Low dose insulin infusion and Placebo infusion.
Who can participate?
Listed age limits: 18 years to 40 years.
Is this study still recruiting?
The registry lists this study as not yet recruiting.
